Published in Br J Cancer on April 24, 2006
Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg (2015) 2.71
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol (2009) 1.59
The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg (2012) 1.51
Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol (2011) 1.32
Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist (2011) 1.27
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol (2012) 1.06
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol (2013) 0.95
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol (2014) 0.92
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Support Care Cancer (2008) 0.90
Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. Ann Surg Oncol (2012) 0.85
Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer. J Thorac Dis (2015) 0.84
Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery. Am J Transl Res (2014) 0.83
Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis. BMC Cancer (2014) 0.81
The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer. Radiat Oncol J (2014) 0.80
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients. J Cancer Res Clin Oncol (2015) 0.79
Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. J Thorac Oncol (2015) 0.79
Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis. J Thorac Dis (2015) 0.78
Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer. World J Surg (2012) 0.77
A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204). Br J Cancer (2008) 0.76
Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer. Lung Cancer (2011) 0.76
Post-operative radiation therapy. Transl Lung Cancer Res (2013) 0.75
Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer. EJC Suppl (2013) 0.75
Prognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment. Thorac Surg Sci (2011) 0.75
The influence of the metastasis pattern of mediastinal lymph nodes on the postoperative radiotherapy's efficacy for the IIIA-pN2 non-small-cell lung cancer: a retrospective analysis of 220 patients. Onco Targets Ther (2016) 0.75
Is tumor location an independent prognostic factor in locally advanced non-small cell lung cancer treated with trimodality therapy? J Thorac Dis (2017) 0.75
Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer. World J Surg (2008) 0.75
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med (1994) 7.25
Regional lymph node classification for lung cancer staging. Chest (1997) 5.13
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med (2000) 4.54
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst (1991) 4.24
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst (1994) 4.21
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst (1996) 3.95
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol (2002) 3.69
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol (1995) 2.89
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst (1995) 2.64
Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer (1999) 1.87
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol (2003) 1.50
High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol (2005) 1.44
Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol (2001) 1.28
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg (1993) 1.26
Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2002) 1.22
Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol (1997) 1.22
Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg (2000) 1.12
Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg (1992) 1.12
Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer (2001) 1.10
Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer (1997) 0.96
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Lung Cancer (2005) 0.88
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. J Clin Oncol (1992) 0.87
A phase II trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer. Lung Cancer (1995) 0.79
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
A SEMI-MICRO METHOD FOR THE DETERMINATION OF REDUCING SUGARS. Plant Physiol (1940) 5.31
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol (2004) 4.78
Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg (2006) 3.98
Mesenteric cysts. Toward less confusion? Dig Surg (2000) 3.78
Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med (1998) 3.21
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 3.03
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst (2009) 2.83
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
A review of the incorporation of complementary and alternative medicine by mainstream physicians. Arch Intern Med (1998) 2.68
[Studies on the course of corneal endothelial regeneration in experimental inflammation]. Doc Ophthalmol (1966) 2.47
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol (2001) 2.39
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol (2006) 2.28
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J (2009) 2.21
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Fatal myocardial infarction after lung resection in a patient with prophylactic preoperative coronary stenting. Br J Anaesth (2004) 2.10
Accuracy and clinical performance of a continuous intra-arterial blood-gas monitoring system during thoracoscopic surgery. Br J Anaesth (1997) 2.10
Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol (2003) 1.94
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood (1997) 1.89
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer (2008) 1.88
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol (2010) 1.85
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol (2007) 1.85
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol (2000) 1.79
Catamenial hemoptysis. Diagnosis with MRI. Chest (1997) 1.74
Clinical behavior of solitary fibrous tumors of the pleura. Ann Thorac Surg (1999) 1.73
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol (2011) 1.73
Three years' experience in video-assisted thoracic surgery (VATS) for spontaneous pneumothorax. J Thorac Cardiovasc Surg (1994) 1.67
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol (2003) 1.66
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol (2001) 1.60
Densitometry for assessment of effect of lung volume reduction surgery for emphysema. Eur Respir J (2007) 1.60
Lung transplantation for lymphangioleiomyomatosis. N Engl J Med (1996) 1.58
A role of Ia-associated invariant chains in antigen processing and presentation. Cell (1989) 1.55
Early and long-term complaints following video-assisted thoracoscopic surgery: evaluation in 173 patients. Eur J Cardiothorac Surg (2000) 1.54
Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation. J Invest Dermatol (2001) 1.54
VATS resection of an oesophageal leiomyoma in a patient with neurofibromatosis Recklinghausen. Eur J Cardiothorac Surg (1997) 1.52
Descending necrotizing mediastinitis: surgical treatment via clamshell approach. Ann Thorac Surg (1996) 1.49
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology (2011) 1.48
Combined chemotherapy and radiotherapy, followed or not by surgery, in squamous cell carcinoma of the esophagus. Ann Oncol (1995) 1.48
Genetic heterogeneity among blue-cone monochromats. Am J Hum Genet (1993) 1.47
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging (2004) 1.47
Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). Leuk Lymphoma (2013) 1.46
Bronchiolitis obliterans after lung transplantation: a review. Chest (1998) 1.45
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
Infrainguinal aneurysm formation in arterialized autologous saphenous vein grafts. J Vasc Surg (1998) 1.44
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol (1996) 1.43
Effects of lung volume reduction surgery for emphysema on diaphragm dimensions and configuration. Am J Respir Crit Care Med (2001) 1.43
Conversion of C-Labeled Acetate to Citric and Malic Acids in the Tomato Fruit. Plant Physiol (1953) 1.42
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer (2011) 1.42
Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ (2003) 1.41
Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest (1999) 1.41
[Nocebo effects and negative suggestion in anesthesia]. Anaesthesist (2014) 1.40
Preharvest nitroprusside flush improves posttransplantation lung function. J Heart Lung Transplant (1997) 1.40
Circulatory failure after anesthesia induction in a patient with severe primary pulmonary hypertension. Anesthesiology (1999) 1.40
TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol (2009) 1.40
Trisomy-18 syndrome caused by translocation or isochromosome formation. A case report with bibliography. J Med Genet (1972) 1.39
Muscle-sparing anterior thoracotomy for one-stage bilateral lung volume reduction operation. Ann Thorac Surg (1998) 1.39
Improvement of drug-induced chronic renal failure in lung transplantation. Transplantation (1999) 1.39
[Controversies in the treatment of carotid stenosis]. Schweiz Med Wochenschr (2000) 1.39
Strategies to increase limited donor resources. Eur Respir J (2004) 1.38
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology (1995) 1.38
Functional assessment of chest wall integrity after methylmethacrylate reconstruction. Ann Thorac Surg (2000) 1.36
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol (2001) 1.35
Preclinical development of a vaccine 'against smoking'. Onkologie (2002) 1.33
High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res (1999) 1.32
Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant (1999) 1.32
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer (1987) 1.26
The Conversion of CO(2) and CH(3)-CO-COOH to Citric and Malic Acids in the Tomato Fruits. Plant Physiol (1956) 1.26
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer (2003) 1.25
Structure of general thoracic surgery in Europe. Eur J Cardiothorac Surg (2001) 1.24
Adventitial cystic disease of the popliteal artery: percutaneous US-guided aspiration. Radiology (1997) 1.24
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res (2000) 1.24
Recommendations for a Global Core Curriculum in Medical Oncology. Ann Oncol (2004) 1.22
Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer (1995) 1.22
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann Oncol (1997) 1.22
Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology (1997) 1.21
Single lung transplantation for adult respiratory distress syndrome after paraquat poisoning. Thorax (1998) 1.20
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol (1998) 1.20
Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl) (2009) 1.20
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol (2005) 1.20
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol (2009) 1.20
In vivo mechanical characterization of human liver. Med Image Anal (2007) 1.19
Diagnostic terminology for reporting thyroid fine needle aspiration cytology: European Federation of Cytology Societies thyroid working party symposium, Lisbon 2009. Cytopathology (2010) 1.19
Visual impairment in Nordic children. II. Aetiological factors. Acta Ophthalmol (Copenh) (1992) 1.18
Orbital presentations of giant cell arteritis. Graefes Arch Clin Exp Ophthalmol (2001) 1.17
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol (2004) 1.17
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol (2011) 1.16